Inhibrx director granted 10,000 options at $95.22

Amended Form 4 for Inhibrx Biosciences corrects director stock option grant to 10,000 options with a $95.22 exercise price and vesting in 2027.

This filing corrects an earlier one, and you can read the original Form 4 if you want to see what changed.

Rhea-AI Filing Summary

Inhibrx Biosciences, Inc. reported that director Kimberly Manhard received a grant of 10,000 stock options on June 3, 2026. The options have an exercise price of $95.22 per share, become fully exercisable on June 3, 2027 subject to continued service, and expire on June 3, 2036. This amended report corrects the number of options originally disclosed and shows Manhard holding 10,000 options after the grant; the filing states the transactions were not made under a Rule 10b5-1 trading plan.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 1 txn

Insider MANHARD KIMBERLY

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	10,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 10,000 contracts (Direct)

Footnotes (1)

1. F1. This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date.

Key Figures

Stock options granted: 10,000 options Exercise price: $95.22 per share Underlying shares: 10,000 shares of common stock +3 more

6 metrics

Stock options granted 10,000 options Grant to director Kimberly Manhard on June 3, 2026

Exercise price $95.22 per share Exercise price for the granted stock options

Underlying shares 10,000 shares of common stock Shares issuable upon exercise of the options

Vesting date June 3, 2027 Date on which the stock option becomes fully exercisable, subject to continued service

Expiration date June 3, 2036 Expiration of the granted stock options if not exercised

Options held after grant 10,000 options Total options held by Kimberly Manhard following the reported transaction

Key Terms

Amended Form 4, stock option, fully exercisable, continued service

4 terms

Amended Form 4 regulatory

"This Amended Form 4 restates the original Form 4 filed on June 4, 2026"

stock option financial

"This stock option will be fully exercisable on June 3, 2027"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

fully exercisable financial

"This stock option will be fully exercisable on June 3, 2027"

continued service other

"subject to the reporting person's continued service through such date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did INBX report in this amended Form 4?

The company reported a grant of 10,000 stock options to director Kimberly Manhard on June 3, 2026, at an exercise price of $95.22 per share, vesting in full on June 3, 2027 and expiring on June 3, 2036.

Why did Inhibrx Biosciences (INBX) file an amended Form 4?

The amended Form 4 restates a prior filing to correct the number of options granted to Kimberly Manhard, which is now reported as 10,000 stock options due to an administrative error in the original report.

When do Kimberly Manhard’s INBX stock options vest and expire?

The stock option grant will become fully exercisable on June 3, 2027, subject to Kimberly Manhard’s continued service through that date, and will expire on June 3, 2036 if not exercised earlier.

What is the exercise price of the INBX stock options granted to Kimberly Manhard?

The options granted to Kimberly Manhard have an exercise price of $95.22 per share, meaning that is the price at which she may purchase Inhibrx Biosciences common stock upon exercise of the options.

How many INBX options does Kimberly Manhard hold after this transaction?

After the reported grant, Kimberly Manhard holds 10,000 stock options on a direct basis, each relating to one share of Inhibrx Biosciences common stock, according to the amended Form 4 disclosure.

Were the INBX option transactions under a Rule 10b5-1 trading plan?

No. The filing indicates that the transactions were not made under a Rule 10b5-1 trading plan, meaning there is no pre-arranged trading plan referenced for this grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 04:22 PM Accepted by SEC EDGAR 09/18/2026 - 04:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MANHARD KIMBERLY

(Last) (First) (Middle)

C/O INHIBRX BIOSCIENCES, INC.

11025 NORTH TORREY PINES ROAD, SUITE 140

(Street)

LA JOLLA CALIFORNIA 92037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inhibrx Biosciences, Inc. [ INBX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
06/04/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$95.22	06/03/2026		A		10,000		06/03/2027(1)	06/03/2036	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

1. This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date.

Remarks:

This Amended Form 4 restates the original Form 4 filed on June 4, 2026 in its entirety to correct the number of options granted to the Reporting Person due to an administrative error.

	/s/ Kelly D. Deck, as attorney-in-fact for Kimberly Manhard	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)